Preventing disease: One billion pigs vaccinated with Ingelvac PRRS MLV®
Landmark is reached 22 years after launch of the vaccine
Porcine Reproductive and Respiratory Syndrome (PRRS) is one of the severest swine diseases globally
Ingelheim, Germany, 26 September 2016 - Veterinarians and farmers across the globe have reached the landmark of protecting one billion sows and pigs against the potentially devastating effects of Porcine Reproductive and Respiratory Syndrome (PRRS) using Ingelvac PRRS MLV ®. The vaccine, which was launched in 1994 in the USA, is currently marketed in 19 countries in Asia, Europe, and North America. It contributes to securing the pigs’ health as well as providing healthy pork for consumers around the world.
PRRS is considered as being one of the severest swine diseases– both from a herd health and an economic perspective. Every year an estimated 1.5 billion pigs are affected by this disease globally.1 With vaccination the economic impact of PRRS, which is higher than 10€/pig in 90% of the cases,2 can be reduced. Prevention of PRRS and other diseases through vaccination not only leads to more efficient livestock farming; it also reduces the need for antibiotics leading to an improved quality of food from animal origin.
Ingelvac PRRS MLV® is a modified live vaccine against PRRS type II that has allowed veterinarians and farmers to increase the productivity of their farms by reducing or eliminating the negative outcomes of a PRRS infection: abortions, piglet mortality, respiratory problems and reduced growth of pigs.
Ingelvac PRRS MLV® is a well established brand globally. It is customers’ number one choice for vaccinating pigs against PRRS in particular because of its safety and efficacy together with the support services provided by Boehringer Ingelheim Animal Health.3
About Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health is the 6th largest animal health business in the world and is committed to providing leading innovative solutions to prevent, treat and cure animal diseases. With 3,800 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about € 1.36 billion in 2015, representing 9% of the corporation’s revenue base. Main brands of Boehringer Ingelheim’s Animal Health portfolio are Ingelvac Circoflex® (2015 sales of € 281 million), Metacam® (2015 sales of € 101 million), Ingelvac® PRRS (2015 sales of € 99 million) and Duramune® (2015 sales of € 88 million). The Boehringer Ingelheim Animal Health Business is global leader in swine vaccines and holds strong positions in companion animal and cattle vaccines as well as in pharmaceutical specialties for animal use. The company researches and develops therapeutic solutions for animals in the US, Germany, China, Mexico and Japan. In its research-driven Animal Health business, Boehringer Ingelheim continually invests around 12% of net sales of the Animal Health business in R&D.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
Intended audiences: This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
1. Based on local and international market research data (data on file).
2. Dennis DiPietre. “Understanding the hidden impact of PRRS”. 9th Asian PRRSpective, 2015.
3. Based on local and international market research data (data on file).